| Co-Investigator(Kenkyū-buntansha) |
森 和彦 京都府立医科大学, 医学(系)研究科(研究院), 講師 (40252001)
上野 盛夫 京都府立医科大学, 医学(系)研究科(研究院), 助教 (40426531)
田代 啓 京都府立医科大学, 医学(系)研究科(研究院), 教授 (10263097)
中野 正和 京都府立医科大学, 医学(系)研究科(研究院), 准教授 (70381944)
佐藤 隆一 京都府立医科大学, 医学(系)研究科(研究院), 助教 (30717533)
吉井 健悟 京都府立医科大学, 医学(系)研究科(研究院), 講師 (90388471)
|
|---|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2019: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2018: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Outline of Final Research Achievements |
Of 833 primary open-angle glaucoma patients having Genome Wide Association Study (GAWS) data, we selected patients using target eye-drop medications for the add-on treatment (i.e., prostaglandin(PG), beta blocker(β), or carbonic anhydrase inhibitor（CAI）). We selected 1075 patients who met inclusion criteria, we performed a GWAS for the IOP reduction rate for each target drug/group; i.e., latanoprost (LA): 93 patients 93 eyes, carteolol(CA) :34 patients 34 eyes, BR: 53 patients 53 eyes, PG :112 patients 112 eyes, β:59 patients 59 eyes, and CAI :58 patients 58 eyes. The number of variants that showed P-value less than ten to the -7th, -6th, -5th power were 2, 4, 49 (LA), and 0 ,3 ,48 (CA), 2, 21, 29 (BR), respectively, and were 2, 18, 133 (PG), 0, 3, 62 (β), 6, 24, 74 (CAI), respectively. As for the variants that showed the small P-values, we are planning to conduct a replication study.
|
